Elevated levels of HMGB1 in cancerous and inflammatory effusions

Anticancer Research

Volumn 29, Issue 12, 2009, Pages 5013-5017

  Winter, Nina ^a   Meyer, Anke ^a   Richter, Andreas ^a   Krisponeit, Dietz ^b   Bullerdiek, Jörn ^a,c  

^a UNIVERSITY OF BREMEN   (Germany)

^b General Hospital Bremen Mitte   (Germany)

^c UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

Author keywords

Angiogenesis; ELISA; Exudates; HMGB1; Transudates

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN;

ADULT; AGED; ARTICLE; ASCITES FLUID; CELL DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXUDATE; HUMAN; INFLAMMATION; NEOPLASM; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN ANALYSIS;

ASCITES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HMGB1 PROTEIN; HUMANS; INFLAMMATION; NECROSIS; NEOPLASM STAGING; PLEURAL EFFUSION, MALIGNANT; PROGNOSIS;

EID: 75149170503     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Muller S, Scaffidi P, Degryse B, Bonaldi T, Ronfani L, Agresti A, Beltrame M and Bianchi ME: New EMBO members' review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal. Embo J 20(16): 4337-4340, 2001.
2. Goodwin GH, Sanders C and Johns EW: A new group of chromatin-associated proteins with a high content of acidic and basic amino acids. Eur J Biochem 38(1): 14-19, 1973.
3. Landsman D and Bustin M: A signature for the HMG-1 box DNA-binding proteins. Bioessays 15(8): 539-546, 1993.
4. Passalacqua M, Patrone M, Picotti GB, Del Rio M, Sparatore B, Melloni E and Pontremoli S: Stimulated astrocytes release high-mobility group 1 protein, an inducer of LAN-5 neuroblastoma cell differentiation. Neuroscience 82(4): 1021-1028, 1998.
5. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U, Molina PE, Abumrad NN, Sama A and Tracey KJ: HMG-1 as a late mediator of endotoxin lethality in mice. Science 285(5425): 248-251, 1999.
6. Scaffidi P, Misteli T and Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418(6894): 191-195, 2002.
7. Parkkinen J and Rauvala H: Interactions of plasminogen and tissue plasminogen activator (t-PA) with amphoterin. Enhancement of t-PA-catalyzed plasminogen activation by amphoterin. J Biol Chem 266(25): 16730-16735, 1991.
8. Hori O, Brett J, Slattery T, Cao R, Zhang J, Chen JX, Nagashima M, Lundh ER, Vijay S, Nitecki D, Morser J, Stern D and Schmidt AM: The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 270(43): 25752-25761, 1995.
9. Schlueter C, Weber H, Meyer B, Rogalla P, Roser K, Hauke S and Bullerdiek J: Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. Am J Pathol 166(4): 1259-1263, 2005.
10. van Beijnum JR, Buurman WA and Griffioen AW: Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high-mobility group B1 (HMGB1). Angiogenesis 11(1): 91-99, 2008.
11. van Beijnum JR, Dings RP, van der Linden E, Zwaans BM, Ramaekers FC, Mayo KH and Griffioen AW: Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. Blood 108(7): 2339-2348, 2006.
12. Huttunen HJ, Fages C, Kuja-Panula J, Ridley AJ and Rauvala H: Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res 62(16): 4805-4811, 2002.
13. Huttunen HJ, Fages C and Rauvala H: Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem 274(28): 19919-19924, 1999.
14. Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA and Schmidt AM: Activation of the receptor for advanced glycation end products triggers a p21 (ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 272(28): 17810-17814, 1997.
15. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, Tanji N, Lu Y, Lalla E, Fu C, Hofmann MA, Kislinger T, Ingram M, Lu A, Tanaka H, Hori O, Ogawa S, Stern DM and Schmidt AM: Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405(6784): 354-360, 2000.
16. Mitola S, Belleri M, Urbinati C, Coltrini D, Sparatore B, Pedrazzi M, Melloni E and Presta M: Cutting edge: extracellular high mobility group box-1 protein is a proangiogenic cytokine. J Immunol 176(1): 12-15, 2006.
17. Brezniceanu ML, Volp K, Bosser S, Solbach C, Lichter P, Joos S and Zornig M: HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J 17(10): 1295-1297, 2003.
18. Flohr AM, Rogalla P, Meiboom M, Borrmann L, Krohn M, Thode-Halle B and Bullerdiek J: Variation of HMGB1 expression in breast cancer. Anticancer Res 21(6A): 3881-3885, 2001.
19. Choi YR, Kim H, Kang HJ, Kim NG, Kim JJ, Park KS, Paik YK, Kim HO and Kim H: Overexpression of high-mobility group box 1 in gastrointestinal stromal tumors with KIT mutation. Cancer Res 63(9): 2188-2193, 2003.
20. Cheng BQ, Jia CQ, Liu CT, Lu XF, Zhong N, Zhang ZL, Fan W and Li YQ: Serum high-mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Dig Liver Dis 40(6): 446-452, 2008.
21. Meyer A, Staratschek-Jox A, Springwald A, Wenk H, Wolf J, Wickenhauser C and Bullerdiek J: Non-Hodgkin lymphoma expressing high levels of the danger-signalling protein HMGB1. Leuk Lymphoma 49(6): 1184-1189, 2008.
22. Joseph J, Badrinath P, Basran GS and Sahn SA: Do we need all three criteria for the diagnostic separation of pleural fluid into transudates and exudates? An appraisal of the traditional criteria. Med Sci Monit 9(11): CR474-476, 2003.
23. Kuiper JJ, van Buuren HR and de Man RA: Ascites in cirrhosis: a review of management and complications. Neth J Med 65(8): 283-288, 2007.
24. Zeh HJ, 3rd and Lotze MT: Addicted to death: invasive cancer and the immune response to unscheduled cell death. J Immunother 28(1): 1-9, 2005.
25. Yang H, Wang H, Czura CJ and Tracey KJ: The cytokine activity of HMGB1. J Leukoc Biol 78(1): 1-8, 2005.
26. Lyons-Boudreaux V, Mody DR, Zhai J and Coffey D: Cytologic malignancy versus benignancy: how useful are the 'newer' markers in body fluid cytology? Arch Pathol Lab Med 132(1): 23-28, 2008.
27. Light RW, Macgregor MI, Luchsinger PC and Ball WC Jr: Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med 77(4): 507-513, 1972.
28. Parkkinen J, Raulo E, Merenmies J, Nolo R, Kajander EO, Baumann M and Rauvala H: Amphoterin, the 30-kDa protein in a family of HMG1-type polypeptides. Enhanced expression in transformed cells, leading edge localization, and interactions with plasminogen activation. J Biol Chem 268(26): 19726-19738, 1993.
29. Messmer D, Yang H, Telusma G, Knoll F, Li J, Messmer B, Tracey KJ and Chiorazzi N: High-mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol 173(1): 307-313, 2004.
30. Ulloa L and Messmer D: High-mobility group box 1 (HMGB1) protein: friend and foe. Cytokine Growth Factor Rev 17(3): 189-201, 2006.
31. Tesniere A, Panaretakis T, Kepp O, Apetoh L, Ghiringhelli F, Zitvogel L and Kroemer G: Molecular characteristics of immunogenic cancer cell death. Cell Death Differ 15(1): 3-12, 2008.